• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Cosmos Health Inc. - Common Stock
Skyward Specialty Insurance Group, Inc. - Common Stock
Solarmax Technology Inc. - Common Stock
Spectaire Holdings, Inc. - Warrants
Edit Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bright Minds Biosciences Inc (CSE:DRUG)

73.03 -3.51 (-4.59%)
Delayed Quote Updated: 9:48 AM EDT, Oct 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 203
Open 73.03
Bid (Size) 72.09 (100)
Ask (Size) 73.33 (100)
Prev. Close 76.54
Today's Range 73.03 - 73.03
52wk Range 68.02 - 170.00
Shares Outstanding N/A
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Bright Minds Biosciences to Participate in the 2026 FPWR Research Symposium and PWS Family Conference
September 30, 2026
From Bright Minds Biosciences
Via GlobeNewswire
News headline image
Bright Minds Biosciences to Present at Jefferies Global Healthcare Conference
May 26, 2026
From Bright Minds Biosciences
Via GlobeNewswire

Performance

52-Week Range 57.0% below 52-week high
73.03
68.0252W Low 170.0052W High
1 Week 6.9% below 1-week high
71.001W Low 78.451W High

Bright Minds Biosciences Inc (DRUG) traded between $68.02 and $170.00 over the past 52 weeks and last traded at $73.03, 57.0% below its 52-week high. Over the past week it ranged between $71.00 and $78.45.

Past 12 Months
-5.3%
-12.8%
-30.0%
-38.8%
-36.9%
-19.7%
1W -$4.07
1M -$10.70
3M -$31.30
6M -$46.22
YTD -$42.77
1Y -$17.86

DRUG was -19.7% over the past year, -38.8% over six months, -36.9% year to date, -5.3% in the last week.

12 Months vs Market
DRUG
-19.7%
DIA
+12.0%
SPY
+14.7%
QQQ
+18.0%
IWM
+7.9%

Over the past 12 months DRUG returned -19.7% versus DIA (Dow) +12.0%, SPY (S&P 500) +14.7%, QQQ (Nasdaq 100) +18.0% and IWM (Russell 2000) +7.9%.

Volume & Liquidity 0.27× 3-mo avg
Today 203 3-mo avg 756.0
1W
636.0
1M
1.0K
3M
756.0
6M
775.0
YTD
922.0
1Y
947.0

DRUG most recently traded 203 shares against a 3-month average daily volume of 756.0.

More News

Read More
News headline image
Bright Minds Biosciences Announces Closing of US$175 Million Public Offering
January 09, 2026
From Bright Minds Biosciences
Via GlobeNewswire
News headline image
Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Leaders in Epilepsy Research
March 04, 2025
From Bright Minds Biosciences
Via GlobeNewswire
News headline image
Bright Minds Biosciences to Participate at Three Healthcare Conferences in March
February 24, 2025
From Bright Minds Biosciences
Via GlobeNewswire
News headline image
Bright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer
January 07, 2025
From Bright Minds Biosciences
Via GlobeNewswire
News headline image
Bright Minds Biosciences to Present Data at the American Epilepsy Society 2024 Annual Meeting
November 21, 2024
From Bright Minds Biosciences
Via GlobeNewswire
News headline image
Bright Minds Biosciences Closes US$35 Million Non-Brokered Private Placement
November 04, 2024
From Bright Minds Biosciences
Via GlobeNewswire
News headline image
Bright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of EEG Data
October 21, 2024
From Bright Minds Biosciences
Via GlobeNewswire
News headline image
Bright Minds Biosciences proprietary compound, BMB-201, 5-HT2C/2A mixed agonist, demonstrated similar efficacy to morphine in preclinical pain models
October 16, 2024
From Bright Minds Biosciences
Via GlobeNewswire
News headline image
Bright Minds Biosciences announces participation in upcoming scientific conferences and partnering events
October 03, 2024
From Bright Minds Biosciences
Via GlobeNewswire
News headline image
Bright Minds Biosciences to Host Investor & Analyst KOL Event on September 25th
September 19, 2024
From Bright Minds Biosciences
Via GlobeNewswire
News headline image
New Study Reveals Psychedelic Drugs Can Be Almost as Life-Changing as Near-Death Experiences
October 05, 2022
Via PressReach
Topics Supply Chain
New Study Reveals Psychedelic Drugs Can Be Almost as Life-Changing as Near-Death Experiences
October 05, 2022
Via FinancialNewsMedia

Frequently Asked Questions

Is Bright Minds Biosciences Inc publicly traded?
Yes, Bright Minds Biosciences Inc is publicly traded.
What exchange does Bright Minds Biosciences Inc trade on?
Bright Minds Biosciences Inc trades on the Canadian Securities Exchange
What is the ticker symbol for Bright Minds Biosciences Inc?
The ticker symbol for Bright Minds Biosciences Inc is DRUG on the Canadian Securities Exchange
What is the current price of Bright Minds Biosciences Inc?
The current price of Bright Minds Biosciences Inc is 73.03
When was Bright Minds Biosciences Inc last traded?
The last trade of Bright Minds Biosciences Inc was at 10/16/26 09:48 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap